CRIS Current Research Information System

GAMBINERI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.882
AS - Asia 6.641
EU - Europa 5.127
SA - Sud America 578
AF - Africa 385
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 5
Totale 20.638
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.744
SG - Singapore 1.783
CN - Cina 1.583
VN - Vietnam 1.543
IT - Italia 1.318
GB - Regno Unito 1.006
DE - Germania 611
HK - Hong Kong 536
SE - Svezia 465
BR - Brasile 431
IN - India 419
FR - Francia 348
RU - Federazione Russa 309
BD - Bangladesh 196
IE - Irlanda 189
UA - Ucraina 189
KR - Corea 141
ZA - Sudafrica 121
NL - Olanda 116
FI - Finlandia 108
JP - Giappone 106
CH - Svizzera 87
TG - Togo 83
CI - Costa d'Avorio 80
CA - Canada 67
EE - Estonia 66
BG - Bulgaria 63
AR - Argentina 60
AT - Austria 51
ID - Indonesia 44
PH - Filippine 43
IQ - Iraq 41
BE - Belgio 38
MX - Messico 34
PL - Polonia 29
SC - Seychelles 27
TR - Turchia 26
NG - Nigeria 24
EC - Ecuador 23
JO - Giordania 23
TH - Thailandia 23
ES - Italia 21
PK - Pakistan 20
TW - Taiwan 20
AU - Australia 17
GR - Grecia 16
IR - Iran 16
CL - Cile 15
AL - Albania 14
LB - Libano 13
PY - Paraguay 13
PE - Perù 12
HR - Croazia 11
RO - Romania 11
UZ - Uzbekistan 11
EG - Egitto 10
MA - Marocco 10
SA - Arabia Saudita 10
VE - Venezuela 10
DK - Danimarca 9
MY - Malesia 9
HN - Honduras 8
IL - Israele 8
LT - Lituania 8
CO - Colombia 7
PT - Portogallo 7
ET - Etiopia 6
JM - Giamaica 6
NO - Norvegia 6
SK - Slovacchia (Repubblica Slovacca) 6
CZ - Repubblica Ceca 5
LV - Lettonia 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
EU - Europa 4
KE - Kenya 4
KZ - Kazakistan 4
NP - Nepal 4
RS - Serbia 4
TN - Tunisia 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
GH - Ghana 3
GT - Guatemala 3
HU - Ungheria 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
OM - Oman 3
SV - El Salvador 3
UY - Uruguay 3
GA - Gabon 2
KW - Kuwait 2
NI - Nicaragua 2
PA - Panama 2
SN - Senegal 2
TT - Trinidad e Tobago 2
ZW - Zimbabwe 2
AO - Angola 1
AW - Aruba 1
Totale 20.615
Salva come PNG Salva come JPEG
Città #
Singapore 1.174
Southend 835
Ashburn 821
Fairfield 740
San Jose 502
Hong Kong 498
Chandler 406
Woodbridge 368
Bologna 363
Houston 336
Seattle 336
Wilmington 320
Ho Chi Minh City 317
Santa Clara 314
Hanoi 295
Hefei 254
Princeton 231
Dong Ket 225
Ann Arbor 217
Cambridge 212
Beijing 204
Dublin 189
Boardman 168
Los Angeles 166
Council Bluffs 143
Lauterbourg 134
New York 132
Seoul 122
Jacksonville 118
Milan 102
Westminster 98
Nanjing 97
Hyderabad 89
Tokyo 88
Lomé 83
Padova 83
Abidjan 80
Buffalo 79
Helsinki 77
Berlin 75
São Paulo 66
Sofia 60
Bern 59
Dallas 56
Haiphong 56
Saint Petersburg 54
Guangzhou 50
Rome 47
Redondo Beach 45
San Diego 45
Da Nang 44
Jinan 44
The Dalles 44
Shenyang 43
Frankfurt am Main 42
Munich 39
Redwood City 39
Changsha 35
Hebei 35
Redmond 35
Bremen 34
Vienna 34
Turin 33
Mülheim 29
Bengaluru 28
Shanghai 27
Orem 26
Phoenix 26
Tianjin 26
Amsterdam 25
Johannesburg 25
Nanchang 25
Norwalk 25
Brussels 24
Nuremberg 24
Des Moines 23
Falls Church 23
San Francisco 23
Zhengzhou 23
Abeokuta 22
Dearborn 22
Jakarta 22
Baghdad 21
Chicago 21
Hải Dương 21
Warsaw 21
Amman 20
Can Tho 20
Olalla 19
Turku 19
Wuhan 19
Florence 18
London 18
Rimini 18
Toronto 18
Atlanta 16
Boydton 15
Chennai 15
Jiaxing 15
Medford 15
Totale 12.927
Salva come PNG Salva come JPEG
Nome #
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial 500
Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome 333
Defining hyperandrogenism in women with polycystic ovary syndrome: A challenging perspective 305
Behavioral, socio-environmental, educational and demographic correlates of excess body weight in Italian adolescents and young adults 264
Insulin sensitizers in polycystic ovary syndrome 246
Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning 236
Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone 232
17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. 230
Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry 229
Androgen Profiling by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women 224
Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women 224
Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism 223
New insights on diabetes in Turner syndrome: results from an observational study in adulthood 217
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. 216
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome 215
The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk 214
Obituary: Renato Pasquali (1946-2019) 213
In memoriam: Renato Pasquali (1946-2019) 210
A comprehensive approach in diagnosing the polycystic ovary syndrome 209
Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism 205
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 202
Efficacy of very low-calorie ketogenic diet with the Pronokal® method in obese women with polycystic ovary syndrome: a 16-week randomized controlled trial 199
Sex hormones, obesity and type 2 diabetes: is there a link? 197
A new interaction to come: Ghrelin and steroid hormones 195
Anti-müllerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? 191
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. 189
Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states 189
Impact of age, body weight and metabolic risk factors on steroid reference intervals in men 188
SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial 187
Psychological aspects of hyperandrogenic states in late adolescent and young women. 186
New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study 186
Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men. 185
The empowerment of translational research: lessons from laminopathies. 184
Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction 182
Clinical assessment of allostatic overload in adolescent and young women with hyperandrogenic states 182
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. 181
Steroid reference intervals in women: influence of menopause, age and metabolism 177
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. 172
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. 171
Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects 170
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. 169
Evolution of cardiovascular risk factors and the risk for cardiovascular events in a Caucasian population with polycystic ovary syndrom 167
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. 166
Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient 165
Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. 163
Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. 163
Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls 162
Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. 162
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin 161
Liraglutide and Renal Outcomes in Type 2 Diabetes. 160
The PCOS Phenotype in Unselected Populations (P-PUP) study: Ethnic variation in population-based normative cut-offs for defining hirsutism 157
Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. 157
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. 156
Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology 155
Hirsutism and virilization 155
No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours 155
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution 154
Metabolic effects of obesity on reproduction. 151
Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. 151
Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. 149
Sindrome dell'ovaio policistico e diabete di tipo 2 148
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 148
Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. 148
Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. 147
Molecular and phenotypical characterization of 10 families with 11ß-hydroxylase deficiency 147
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors 147
An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. 147
Prevalence and ultrasound patterns of testicular adrenal rest tumors in adults with congenital adrenal hyperplasia 147
Biomediators in polycystic ovary syndrome and cardiovascular risk 147
Is it possible to achieve an acceptable disease control by dietary therapy alone in Berardinelli Seip type 1? Experience from a case report 145
Ghrelin and reproductive disorders. 145
High serum concentration of total inhibin in polycystic ovary syndrome 144
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. 143
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS 141
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. 140
Liraglutide and cardiovascular outcomes in type 2 diabetes 140
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors 139
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome 137
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS? 137
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. 137
Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects 137
The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE) 136
Quality of diet, screened by the Mediterranean diet quality index and the evaluation of the content of advanced glycation endproducts, in a population of high school students from Emilia Romagna 134
Targeting insulin sensitivity in the treatment of polycystic ovary syndrome 134
The impact of obesity on reproduction in women with polycystic ovary syndrome. 132
Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students 131
Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction 131
Insulin-sensitizing agents in polycystic ovary syndrome. 129
The role of low-grade inflammation in the polycystic ovary syndrome. 128
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity 128
Delphi consensus on the diagnostic criteria of polycystic ovary syndrome 126
Mechanisms and treatment of obesity in polycystic ovary syndrome 123
Role of changes in dietary habits in polycystic ovary syndrome. 123
Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions 123
Validation of an LC–MS/MS salivary assay for glucocorticoid status assessment: Evaluation of the diurnal fluctuation of cortisol and cortisone and of their association within and between serum and saliva 121
Parallel diurnal fluctuation of testosterone, androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in serum and saliva: validation of a novel liquid chromatography-tandem mass spectrometry method for salivary steroid profiling 121
Radioiodine whole body scan pitfalls in differentiated thyroid cancer 120
Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C 120
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 119
Type 2 diabetes and the polycystic ovary syndrome. 118
Totale 17.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.729
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.729
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021404 0 0 0 0 0 0 0 0 0 0 0 404
2021/20221.999 161 57 119 132 193 94 71 165 73 134 478 322
2022/20232.170 233 295 93 305 148 131 69 114 350 165 158 109
2023/2024728 77 116 54 48 54 114 53 48 16 77 48 23
2024/20252.882 108 445 272 185 411 148 212 101 69 214 159 558
2025/20267.966 576 689 661 618 746 421 1.003 286 1.415 624 516 411
Totale 20.984